Breakdown | |||||
TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
20.87B | 20.18B | 19.37B | 18.87B | 20.25B | 17.12B | Gross Profit |
9.29B | 9.13B | 8.17B | 8.48B | 9.43B | 7.58B | EBIT |
2.36B | 2.40B | 2.11B | 2.28B | 2.80B | 1.48B | EBITDA |
3.52B | 4.82B | 4.28B | 4.29B | 4.25B | 2.97B | Net Income Common Stockholders |
1.50B | 1.71B | 1.48B | 1.78B | 2.09B | 874.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
683.00M | 2.16B | 1.42B | 1.01B | 2.29B | 2.85B | Total Assets |
54.47B | 57.29B | 52.78B | 52.93B | 53.87B | 54.01B | Total Debt |
19.27B | 20.11B | 15.88B | 16.07B | 17.61B | 17.93B | Net Debt |
18.60B | 18.39B | 14.46B | 15.06B | 15.33B | 15.11B | Total Liabilities |
29.23B | 31.40B | 26.98B | 27.63B | 30.19B | 30.24B | Stockholders Equity |
25.24B | 25.89B | 25.80B | 25.30B | 23.68B | 23.77B |
Cash Flow | Free Cash Flow | ||||
2.59B | 3.07B | 2.12B | 1.66B | 3.42B | 2.73B | Operating Cash Flow |
3.30B | 3.80B | 2.99B | 2.63B | 4.65B | 3.54B | Investing Cash Flow |
-4.21B | -5.51B | -716.00M | -3.23B | -1.88B | -1.23B | Financing Cash Flow |
-723.00M | 2.09B | -1.96B | -591.00M | -3.31B | 22.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
85 Outperform | $36.90B | 28.26 | 25.81% | 0.84% | 9.54% | 37.23% | |
75 Outperform | $16.11B | 35.22 | 17.42% | 0.37% | -1.14% | -16.35% | |
70 Outperform | $14.53B | 27.08 | 11.77% | ― | 1.66% | 21.95% | |
69 Neutral | $13.91B | 33.35 | 5.15% | ― | 6.88% | 21.11% | |
68 Neutral | $49.33B | 32.84 | 5.97% | 2.45% | 5.84% | 15.12% | |
61 Neutral | $15.82B | 136.07 | -8.96% | 2.21% | -20.17% | -138.32% | |
54 Neutral | $5.25B | 3.29 | -44.34% | 6.27% | 16.79% | -0.10% |
Becton, Dickinson and Company (BD) is involved in a legal matter concerning stockholder derivative actions. A proposed settlement has been reached in the consolidated stockholder derivative litigation against BD and certain of its officers and directors, which alleges breaches of fiduciary duties and other misconduct related to the Alaris infusion pump system. The settlement, if approved by the court, will resolve the litigation and prevent further claims related to the issues. A settlement hearing is scheduled for August 11, 2025, to determine the fairness of the settlement terms.
The most recent analyst rating on (BDX) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.
On March 26, 2025, Gregory J. Hayes was elected to the Board of Directors of Becton Dickinson, expanding the Board from eleven to twelve members. Hayes will serve on the Audit Committee and the Compensation and Human Capital Committee, and his appointment reflects BD’s adherence to corporate governance principles, potentially strengthening its board’s oversight capabilities.